Vascularized tissue-engineered model for studying drug resistance in neuroblastoma

A. Villasante, Katsuhisa Sakaguchi, J. Kim, N. K. Cheung, M. Nakayama, H. Parsa1, T. Okano, T. Shimizu, G. Vunjak-Novakovic

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Neuroblastoma is a vascularized pediatric tumor derived from neural crest stem cells that displays vasculogenic mimicry and can express a number of stemness markers, such as SOX2 and NANOG. Tumor relapse is the major cause of succumbing to this disease, and properties attributed to cancer stem-like cells (CSLC), such as drug-resistance and cell plasticity, seem to be the key mechanisms. However, the lack of controllable models that recapitulate the features of human neuroblastoma limits our understanding of the process and impedes the development of new therapies. In response to these limitations, we engineered a perfusable, vascularized in vitro model of three-dimensional human neuroblastoma to study the effects of retinoid therapy on tumor vasculature and drug-resistance. METHODS: The in vitro model of neuroblastoma was generated using cell-sheet engineering and cultured in a perfusion bioreactor. Firstly, we stacked three cell sheets containing SKNBE(2) neuroblastoma cells and HUVEC. Then, a vascular bed made of fibrin, collagen I and HUVEC cells was placed onto a collagen-gel base with 8 microchannels. After gelling, the stacked cell sheets were placed on the vascular bed and cultured in the perfusion bioreactor (perfusion rate: 0.5 mL/min) for 4 days. Neuroblastoma models were treated with 10μM isotretionin in single daily doses for 5 days. RESULTS: The bioengineered model recapitulated vasculogenic mimicry (vessel-like structure formation and tumor-derived endothelial cells-TECs), and contained CSLC expressing SOX2 and NANOG. Treatment with Isotretinoin destabilized vascular networks but failed to target vasculogenic mimicry and augmented populations of CSLCs expressing high levels of SOX2. Our results suggest that CSLCs can transdifferentiate into drug resistant CD31+-TECs, and reveal the presence of an intermediate state STEC (stem tumor-derived endothelial cell) expressing both SOX2 and CD31. CONCLUSION: Our results reveal some roles of SOX2 in drug resistance and tumor relapse, and suggest that SOX2 could be a therapeutic target in neuroblastoma.

Original languageEnglish
Article number20730
JournalTheranostics
Volume7
Issue number17
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Neuroblastoma
Drug Resistance
Blood Vessels
Neoplasms
Neoplastic Stem Cells
Perfusion
Human Umbilical Vein Endothelial Cells
Bioreactors
Collagen
Endothelial Cells
Cell Engineering
Recurrence
Isotretinoin
Neural Stem Cells
Neural Crest
Retinoids
Fibrin
Therapeutics
Gels
Pediatrics

Keywords

  • Bioengineering
  • Cell plasticity
  • Neuroblastoma
  • Perfusion bioreactor
  • SOX2
  • Vasculogenic mimicry

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Villasante, A., Sakaguchi, K., Kim, J., Cheung, N. K., Nakayama, M., Parsa1, H., ... Vunjak-Novakovic, G. (2017). Vascularized tissue-engineered model for studying drug resistance in neuroblastoma. Theranostics, 7(17), [20730]. https://doi.org/10.7150/thno.20730

Vascularized tissue-engineered model for studying drug resistance in neuroblastoma. / Villasante, A.; Sakaguchi, Katsuhisa; Kim, J.; Cheung, N. K.; Nakayama, M.; Parsa1, H.; Okano, T.; Shimizu, T.; Vunjak-Novakovic, G.

In: Theranostics, Vol. 7, No. 17, 20730, 01.01.2017.

Research output: Contribution to journalArticle

Villasante, A, Sakaguchi, K, Kim, J, Cheung, NK, Nakayama, M, Parsa1, H, Okano, T, Shimizu, T & Vunjak-Novakovic, G 2017, 'Vascularized tissue-engineered model for studying drug resistance in neuroblastoma', Theranostics, vol. 7, no. 17, 20730. https://doi.org/10.7150/thno.20730
Villasante, A. ; Sakaguchi, Katsuhisa ; Kim, J. ; Cheung, N. K. ; Nakayama, M. ; Parsa1, H. ; Okano, T. ; Shimizu, T. ; Vunjak-Novakovic, G. / Vascularized tissue-engineered model for studying drug resistance in neuroblastoma. In: Theranostics. 2017 ; Vol. 7, No. 17.
@article{f5d441e6a0f74ca98df97090b446100a,
title = "Vascularized tissue-engineered model for studying drug resistance in neuroblastoma",
abstract = "Neuroblastoma is a vascularized pediatric tumor derived from neural crest stem cells that displays vasculogenic mimicry and can express a number of stemness markers, such as SOX2 and NANOG. Tumor relapse is the major cause of succumbing to this disease, and properties attributed to cancer stem-like cells (CSLC), such as drug-resistance and cell plasticity, seem to be the key mechanisms. However, the lack of controllable models that recapitulate the features of human neuroblastoma limits our understanding of the process and impedes the development of new therapies. In response to these limitations, we engineered a perfusable, vascularized in vitro model of three-dimensional human neuroblastoma to study the effects of retinoid therapy on tumor vasculature and drug-resistance. METHODS: The in vitro model of neuroblastoma was generated using cell-sheet engineering and cultured in a perfusion bioreactor. Firstly, we stacked three cell sheets containing SKNBE(2) neuroblastoma cells and HUVEC. Then, a vascular bed made of fibrin, collagen I and HUVEC cells was placed onto a collagen-gel base with 8 microchannels. After gelling, the stacked cell sheets were placed on the vascular bed and cultured in the perfusion bioreactor (perfusion rate: 0.5 mL/min) for 4 days. Neuroblastoma models were treated with 10μM isotretionin in single daily doses for 5 days. RESULTS: The bioengineered model recapitulated vasculogenic mimicry (vessel-like structure formation and tumor-derived endothelial cells-TECs), and contained CSLC expressing SOX2 and NANOG. Treatment with Isotretinoin destabilized vascular networks but failed to target vasculogenic mimicry and augmented populations of CSLCs expressing high levels of SOX2. Our results suggest that CSLCs can transdifferentiate into drug resistant CD31+-TECs, and reveal the presence of an intermediate state STEC (stem tumor-derived endothelial cell) expressing both SOX2 and CD31. CONCLUSION: Our results reveal some roles of SOX2 in drug resistance and tumor relapse, and suggest that SOX2 could be a therapeutic target in neuroblastoma.",
keywords = "Bioengineering, Cell plasticity, Neuroblastoma, Perfusion bioreactor, SOX2, Vasculogenic mimicry",
author = "A. Villasante and Katsuhisa Sakaguchi and J. Kim and Cheung, {N. K.} and M. Nakayama and H. Parsa1 and T. Okano and T. Shimizu and G. Vunjak-Novakovic",
year = "2017",
month = "1",
day = "1",
doi = "10.7150/thno.20730",
language = "English",
volume = "7",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "17",

}

TY - JOUR

T1 - Vascularized tissue-engineered model for studying drug resistance in neuroblastoma

AU - Villasante, A.

AU - Sakaguchi, Katsuhisa

AU - Kim, J.

AU - Cheung, N. K.

AU - Nakayama, M.

AU - Parsa1, H.

AU - Okano, T.

AU - Shimizu, T.

AU - Vunjak-Novakovic, G.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Neuroblastoma is a vascularized pediatric tumor derived from neural crest stem cells that displays vasculogenic mimicry and can express a number of stemness markers, such as SOX2 and NANOG. Tumor relapse is the major cause of succumbing to this disease, and properties attributed to cancer stem-like cells (CSLC), such as drug-resistance and cell plasticity, seem to be the key mechanisms. However, the lack of controllable models that recapitulate the features of human neuroblastoma limits our understanding of the process and impedes the development of new therapies. In response to these limitations, we engineered a perfusable, vascularized in vitro model of three-dimensional human neuroblastoma to study the effects of retinoid therapy on tumor vasculature and drug-resistance. METHODS: The in vitro model of neuroblastoma was generated using cell-sheet engineering and cultured in a perfusion bioreactor. Firstly, we stacked three cell sheets containing SKNBE(2) neuroblastoma cells and HUVEC. Then, a vascular bed made of fibrin, collagen I and HUVEC cells was placed onto a collagen-gel base with 8 microchannels. After gelling, the stacked cell sheets were placed on the vascular bed and cultured in the perfusion bioreactor (perfusion rate: 0.5 mL/min) for 4 days. Neuroblastoma models were treated with 10μM isotretionin in single daily doses for 5 days. RESULTS: The bioengineered model recapitulated vasculogenic mimicry (vessel-like structure formation and tumor-derived endothelial cells-TECs), and contained CSLC expressing SOX2 and NANOG. Treatment with Isotretinoin destabilized vascular networks but failed to target vasculogenic mimicry and augmented populations of CSLCs expressing high levels of SOX2. Our results suggest that CSLCs can transdifferentiate into drug resistant CD31+-TECs, and reveal the presence of an intermediate state STEC (stem tumor-derived endothelial cell) expressing both SOX2 and CD31. CONCLUSION: Our results reveal some roles of SOX2 in drug resistance and tumor relapse, and suggest that SOX2 could be a therapeutic target in neuroblastoma.

AB - Neuroblastoma is a vascularized pediatric tumor derived from neural crest stem cells that displays vasculogenic mimicry and can express a number of stemness markers, such as SOX2 and NANOG. Tumor relapse is the major cause of succumbing to this disease, and properties attributed to cancer stem-like cells (CSLC), such as drug-resistance and cell plasticity, seem to be the key mechanisms. However, the lack of controllable models that recapitulate the features of human neuroblastoma limits our understanding of the process and impedes the development of new therapies. In response to these limitations, we engineered a perfusable, vascularized in vitro model of three-dimensional human neuroblastoma to study the effects of retinoid therapy on tumor vasculature and drug-resistance. METHODS: The in vitro model of neuroblastoma was generated using cell-sheet engineering and cultured in a perfusion bioreactor. Firstly, we stacked three cell sheets containing SKNBE(2) neuroblastoma cells and HUVEC. Then, a vascular bed made of fibrin, collagen I and HUVEC cells was placed onto a collagen-gel base with 8 microchannels. After gelling, the stacked cell sheets were placed on the vascular bed and cultured in the perfusion bioreactor (perfusion rate: 0.5 mL/min) for 4 days. Neuroblastoma models were treated with 10μM isotretionin in single daily doses for 5 days. RESULTS: The bioengineered model recapitulated vasculogenic mimicry (vessel-like structure formation and tumor-derived endothelial cells-TECs), and contained CSLC expressing SOX2 and NANOG. Treatment with Isotretinoin destabilized vascular networks but failed to target vasculogenic mimicry and augmented populations of CSLCs expressing high levels of SOX2. Our results suggest that CSLCs can transdifferentiate into drug resistant CD31+-TECs, and reveal the presence of an intermediate state STEC (stem tumor-derived endothelial cell) expressing both SOX2 and CD31. CONCLUSION: Our results reveal some roles of SOX2 in drug resistance and tumor relapse, and suggest that SOX2 could be a therapeutic target in neuroblastoma.

KW - Bioengineering

KW - Cell plasticity

KW - Neuroblastoma

KW - Perfusion bioreactor

KW - SOX2

KW - Vasculogenic mimicry

UR - http://www.scopus.com/inward/record.url?scp=85030645514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030645514&partnerID=8YFLogxK

U2 - 10.7150/thno.20730

DO - 10.7150/thno.20730

M3 - Article

VL - 7

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 17

M1 - 20730

ER -